1,981 Shares in Stryker Corporation $SYK Purchased by Montecito Bank & Trust

by · The Markets Daily

Montecito Bank & Trust bought a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,981 shares of the medical technology company’s stock, valued at approximately $732,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Mid American Wealth Advisory Group Inc. purchased a new position in Stryker in the second quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $28,000. Sachetta LLC grew its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. Kilter Group LLC purchased a new position in shares of Stryker during the 2nd quarter worth $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in Stryker in the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Stryker stock opened at $353.03 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. The company has a fifty day simple moving average of $365.45 and a 200-day simple moving average of $377.69. The stock has a market cap of $135.01 billion, a P/E ratio of 46.39, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is 44.15%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research analyst reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. BTIG Research reiterated a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Monday. Barclays raised their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $431.39.

View Our Latest Stock Report on SYK

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also